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Abstract
The RAS (rat sarcoma) superfamily of small GTPases is broadly subdivided into five groups: Ras, Rho, Rab, Ran, and
Arf. Rab family proteins are important in regulating signal transduction and cellular processes such as differentia-
tion, proliferation, vesicle transport, nuclear assembly, and cytoskeleton formation. However, some Rab proteins
have been reported to be necessary for the adhesion and migration of cancer cells. Although Ras and Rho family
members have been strongly implicated in cancer progression, knowledge of Rabs action in this regard is limited.
Some reports have also linked Rab GTPases with cancer cell migration and invasiveness. This review discusses the
implications of the involvement of Rabs in malignant transformation and cancer therapy through integrin-mediated
signaling events, with particular emphasis on breast cancer.
Introduction
Ras-associated binding (Rab)-GTPases are members of
the Ras family of small GTPases. They are abnormally
expressed in different cancer tissues. Almost 70 Rabs and
Rab-like proteins are encoded by the human genome.
Some of these are tissue-specific; most of them are ubi-
quitously expressed (Figure 1). Rabs participate in recep-
tor cargo collection during transport vesicle formation
and enable motor proteins to interact with membranes to
drive vesicle motility, mediating the complex events of
accurate docking and fusion of transport vesicles with
their targets. Protein-protein interactions are important
for localization of Rabs in mammalian cells [1].
Rab GTPases mediate vesicle formation and vesicle
movement along with actin and tubulin, and membrane
fusion [2]. This process is involved in cell migration
with lamellipodial formation. The Rab subfamily termi-
nates in a set of cysteine-containing C-terminal motifs
that allow modification of Rab GTPases to various
membrane locations by geranyl-geranyl transferase II
[3]. The Rab regulators promote a switch between the
GDP-bound off-state and a GTP-bound on-state. The
switch between GDP and GTP bound forms of Rab
GTPases occurs through major conformational changes
in two variable regions, Switch I and Switch II. GDP to
GTP conversion is catalyzed by guanine nucleotide
exchange factors (GEFs), which recognize particular
residues in the switch regions and cause GDP release.
The switch from GTP to the GDP bound form occurs
through GTP hydrolysis, which is catalyzed by GTPase-
activating proteins (GAPs) [4,5]. At times, Rab GTPases
exist in GDP bound forms. This is caused by Rab
GTPase dissociation inhibitor (GDI), which prevents the
release of GDP from Rab. For specific recognition, a
vesicle and its target are coded by a unique compliment
of Rab GTPases [6]. Thus, it is important to understand
the intracellular signaling of Rab proteins in various
cells to find new molecular approaches to cancer biol-
ogy. We briefly summarize the functions of all major
Rab proteins in vesicular trafficking; describe their func-
tion in endosomes and the importance of Rabs in cancer
biology; and discuss the importance of integrins in the
regulation of Rab functions.
Localization and function of Rab GTPases
A total of 51 Rab and Rab-related proteins have been
functionally characterized. As shown in Figure 1, several
Rabs are localized in endoplasmic reticulum (ER) and
involved in transport from ER to Golgi. Some Rabs are
localized in endosomes, clathrin-coated vesicles, plasma
membrane, membrane ruffles, and secretory granules
(Figure 1). These Rabs have a wide variety of functions
that include, but not limited to, trafficking between
Golgi and endosomes, phagocytosis, the assembly of
adherens junctions, trafficking of sonic hedgehog
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Figure 1 Rab GTPases are involved in vesicle transport and trafficking. Some examples of Rab functions are shown. Rab 1a is localized pre-
Golgi intermediates, and Rab 1b, 2a and 2b, which are localized in the ER, are important in transport from the ER to Golgi. Rab6a, 6b, and 33b
are involved in intra-Golgi transport, as well as transport from the Golgi apparatus to the ER. Rab 11a and Rab17 are involved in transport
through apical recycling endosomes. Rab14 and 22a contribute to transport from phagosomes to late endosomes. Rab9a, 9b, and 9c are
involved in late endosome to Golgi transport. Rab7b participates in transport from endosomes to the TGN, while Rab12 is involved in transport
from the cell periphery to the centrosome. Rab 5 and 14 are localized in early endosome and Rab 4 is localized in recycled enodosmes. Rab18 is
involved in transport from ER to lipid droplets; Rab10, from Golgi to the basolateral membrane; Rab 26, 27a, 27b, 37, 11b and 3a-d, from Golgi to
secretory granules; Rab22b and Rab11a, from Golgi to endosomes; and Rab6a’, 22a and 14, from endosomes to Golgi. Rab 32 is localized in
mitochondria and regulates mitochondrial dynamics.
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signaling components, mitochondrial dynamics, and
neuroendocrine secretion (Figure 1, Additional File 1).
Here we briefly discuss the function of Rab and Rab-
related proteins in membrane trafficking.
Rab GTPases are involved in regulating membrane
trafficking between organelles through the recruitment
of effector proteins. Immunodeficiencies, cancer, and
neurological disorders are associated with functional
impairments of Rab signaling pathways. Many important
reports have linked Rab GTPases to cancer cell migra-
tion and invasiveness. The two Rab GTPases, Rab5 and
Rab21, are associated with subunits of alpha-integrin,
altering their endosomal traffic and subcellular
localizations.
The regulated trafficking of vesicles to the cell surface
is fundamental to all cells. Rab proteins are key media-
tors of vesicle transport. Rab GTPases are important in
delivering cargos to correct destinations and control
vesicle budding, as well as the uncoating and motility of
vesicles. Rab GTPases, with the help of their effectors
ensure the spatio-temporal regulation of vesicle traffic.
Furthermore, temporal and spatial regulation of mem-
brane trafficking events is important for membrane
identity and cell polarity.
Although the exact mechanism of targeting different
Rab GTPases is not clear, membrane-bound GDI displa-
cement factors have an important function in recogniz-
ing specific Rab GDI complexes and allowing GDI
release. This release helps in the association between
geranyl-geranylated Rab GTPases and the appropriate
membranes. An important step in intracellular traffick-
ing is cargo selection into specific transport vesicles.
Membrane curvature, lipid composition, and Rab
GTPases determine the specific coat recruitment to par-
ticular intracellular membranes. Rab 9 and Rab 5 are
two good examples of Rab GTPases that are involved in
cargo selection [7,8]. Rab 9 is involved in cargo specific-
coat assembly for the recycling of mannose phosphate
receptors from late endosomes to the trans-Golgi net-
work. Rab 5 is important in cargo sequestration, and is
crucial for the assembly of clathrin-coated pits and cla-
thrin-mediated endocytosis of transferring receptors.
Some Rab GTPases control several crucial events in
vesicle budding from donor membranes, including coat
assembly, cargo selection, and physical budding. Vesicle
coat complexes are important for cargo sequestration
and membrane budding; however, the coat complexes
interfere with membrane fusion and thus need to be
shed before association with an acceptor membrane can
occur. For example, Rab5, the GEF and GAP of Rab 5
are involved in uncoating events [9]. Actin filaments
and microtubules regulate the direction and accuracy of
vesicle delivery. Rab GTPases proofread the specific
attachment of motors to vesicles. For example, Rab 27A
recruits melanophilin to connect melanosomes to myo-
sin Va [10]. Rab GTPases also mediate vesicle docking
or fusion. Some Rab GTPases enhance fusion of TGN-
derived vesicles with the plasma membrane. Rab5 is
required for homotypic early endosome fusion and the
fusion of endocytic vesicles to endosomes [11].
Several reports have indicated that Rab proteins can
bind to various proteins to facilitate membrane trans-
port [reviewed in[12]]. Active Rab proteins are also
required for vesicle budding. Membrane budding to
form vesicles involves interaction between several pro-
teins. First, Rab proteins are recruited and activated at
the donor membrane, where they are important in vesi-
cle budding. Second, Rab proteins facilitate transport
along the cytoskeleton. Finally, they are involved in
docking and fusion. Thus, Rab proteins control several
events during vesicular transport [12].
Involvement of Rab GTPases in different Cancers
Some Rab GTPases regulate tumorigenesis via traffick-
ing mediated events and some function in a trafficking
independent way (Figure 2). In this section, we will dis-
cuss both of them.
Trafficking-dependent tumorigenic regulators
Although Rab proteins are involved in intracellular vesi-
cle transport, they also have a major role in cancer
Figure 2 Role of Rab25 in cancer. Activated Rab 25 and other
growth factor receptors are located near the cell surface. Rab25
regulates receptor internalization, vesicle formation, and trafficking
with specific cellular components. Rab25 also activates AKT, which
increases cell proliferation and survival. Rab25 integration leads to
down-regulation of BAX and BAK to activate the Bcl2 pathway,
which affects apoptosis and cell survival.
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progression. Here we mainly focus on Rab proteins,
which are especially important in this respect. In parti-
cular, the role of Rab25 in cancer progression has been
studied at great length.
The role of RAB 25 in cancer Rab25, a 28-kDa protein
also referred to as Rab11c, is involved in cell prolifera-
tion and protection from apoptosis. It has high levels of
expression in ovarian and breast cancers, in which it has
been shown to have a key function in both in vitro and
in vivo cancer progression [13-15]. Increased expression
of Rab25 has also been noted in prostate cancer [16]
and transitional cell carcinoma of the bladder [17], indi-
cating that it has a pathological role in tumor progres-
sion in several epithelial lineages. Reports indicate that
Rab25 is involved in tumor progression by regulating
the localization of integrin-recycling vesicles to enhance
tumor invasion (Figure 2).
Rab25 has been shown to decrease apoptosis, as well as
to increase both the proliferation and aggressiveness of
ovarian and breast cancer [18]. Regulation of cell survival
is mediated by antiapoptotic molecules such as Bcl-2,
BAX, BAK, and phosphoinositide-3-kinase [19,20].
Forced expression of Rab25 in ovarian cancer cells
decreases levels of BAX and BAK [21] and increases
AKT phosphorylation, which in turn activates the phos-
phoinositide-3-kinase pathway. Down-regulation of
Rab25 reverses apoptotic signaling through BAK and
BAX protein signaling, as well as AKT activity. The Bcl-2
and phosphoinositide-3-kinase pathways are enhanced by
Rab25-mediated signaling for cell survival (Figure 2)[18].
Goldenring et al. [22] demonstrated that Rab 25
expression is increased in colon cancer cells. Mills and
colleagues [14] showed that 1q22 amplicon containing
Rab25 is amplified in 50% of ovarian cancers. Further in
vivo studies confirmed that expression of Rab25
increases ovarian tumor growth. In addition, chromo-
some 1q is gained in 50% of breast cancer patients.
Cheng and colleagues[23] showed high expression of
Rab25 in 92% of ER-positive samples and loss of expres-
sion in 83% ER-negative and PR-negative samples of
basal and triple-negative tumors. These findings suggest
that Rab25 may have different functions in different
subtypes of breast cancer. In addition, Rab 25 is overex-
pressed in Wilms tumor, early-stage transitional cell car-
cinoma of the bladder, and hepatocellular carcinoma.
In contrast, Rab25 has also been shown to function as
a tumor suppressor; its expression is lost in hormonally
insensitive breast tumors [24]. Another recent study
indicated that Rab25 may function as a tumor suppres-
sor in intestinal cells. This study demonstrates that loss
of Rab25 leads to increased tumorigenesis through
alteration in the regulation of protein trafficking to the
cell surface. These findings suggest that Rab 25 func-
tions as a tumor suppressor in the intestinal mucosa
and leading to human colorectal adenocarcinoma [25].
Rab25 knockdown by shRNA shows less proliferation,
more apoptosis, and decreased ovarian tumor growth
both in vitro and in vivo [13]. Studies on human breast
cancer tissues have shown that loss of Rab25 expression
occurs through a mutation in locus 1q22-23. Thus,
Rab25 could be used as a biological marker of breast
cancer [23].
Rab5 regulates the fusogenic properties of early endo-
somes through GTP-dependent recruitment and activa-
tion of effector proteins. Defective Rab5 causes the
formation of enlarged multivesicular endosomes with
many intraluminal vesicles; endosomes with early and
late endocytic markers are frequently observed in the
presence of defective Rab5. Inactive Rab5 is defective in
sorting EGF receptor and transferrin receptor [26].
Cdc42 interacting protein-4 (CIP-4) localizes to vesicles
with EGFR and the small GTPase Rab5. In giant endo-
somes, expression of constitutively active Rab5 leads to
the accumulation of CIP-4 and related adaptor Toca-1.
Downregulation of CIP-4 expression in A431 epider-
moid carcinoma cells causes elevation of EGFR but, sur-
prisingly, does not affect surface expression of EGFR
[27]. Thus, understanding the function of Rab5 in EGFR
signaling will be of great interest.
Rab5 guanine nucleotide exchange factor Rin1, which
is activated by Ras, is important in growth-factor recep-
tor trafficking in fibroblasts and endocytosis. Rin1 is
highly expressed in the lung adenocarcinoma cell lines
Hop62, H650, HCC4006, HCC827, EKVX, HCC2935,
and A549. Cell proliferation is reduced by depletion of
Rin1 in A549 cells, and is correlated with a decrease in
EGFR signaling. Thus, Tomshine et al proposed not
only that EGFR-mediated signaling essentially requires
proper internalization and endocytic trafficking, but that
upregulation of Rab5 guanine nucleotide exchange fac-
tor Rin1 may be involved in the proliferative pathway in
A549 cells [28].
Rab11 co-localizes with insulin-containing granules in
the mouse insulin-secreting cell line MIN6. Overexpres-
sion of Rab11B inhibits insulin secretion, indicating its
involvement in regulating insulin secretion. Rip11, an
effector of Rab11, is a substrate for PKA, which regu-
lates exocytosis in pancreatic b-cells [29]. Rip11, which
participates in insulin granule exocytosis, also has been
reported to regulate the recycling of internalized cell-
surface proteins from the early endosome through a
trans-Golgi network. Expression of Rip11 is higher in
ductal carcinoma in situ (DCIS) than it is in normal
breast epithelium. Rab11a influences EGFR recycling,
enhances proliferation, and prevents motility of an
immortal breast cell line (MCF 10A), which is consistent
with the phenotype of DCIS [30]. Rab11a and Rab11-
family interacting protein 2 (FIP2) are involved in the
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regulation of plasma membrane recycling in epithelial
cells. The phosphorylation of Rab11-FIP2 on serine 227
by MARK2 is required for epithelial cell polarity [31].
EGFR, which initiates many biochemical pathways to
potentiate physiological responses, also has an important
part in cancer progression. The recycling of EGFR and
its signaling pathway is regulated by the endocytic path-
way [32]. ADP-ribosylation factor 6 (Arf6), a regulator
of cytoskeletal dynamics during cell movement, binds
with protein FIP3, which interacts with Arf6 and Rab11.
Both Arf6 and Rab11 appear to be involved in regulating
cell motility. MDA-MB-231 breast cancer cells require
FIP3 for motility. FIP3 also is involved in regulating the
localization of Arf6 in MDA-MB-231 breast cancer cells
and polarization of Rac1 [33].
The Rab-coupling protein RCP (RAB11FIP1), located
on chromosome 8p11-12, encodes for a protein with
Ras-activating function. RCP is frequently amplified in
breast cancer. An in-vitro study with normal human
mammary epithelial cells (MCF10A) has shown that
overexpression of RCP not only increases loss of contact
inhibition, growth-factor independence, and anchorage-
independent growth, but also promotes Ras activation
and ERK phosphorylation. Consistent with this, knock-
down of RCP inhibits tumor formation and metastasis
in a xenograft model [34]. Rab11 and the Eps15 homol-
ogy domain 1 (EAD1) regulate the exit of internalized
molecules from endocytic recycling to the plasma mem-
brane. Thus, coordination between Rab11 and EAD pro-
teins occurs in the mediation of endocytic recycling [35].
Rab27A is involved in exocytosis of endocrine cells
and is associated with the invasive and metastatic poten-
tial of breast cancer, promoting the secretion of insulin-
like growth factor-II (IGF-II). The rate of secretion
controls the expression of vascular endothelial growth
factor, matrix metalloproteinase-9 (MMP-9), cathepsin
D, cyclin D1, p16, and urokinase-type plasminogen acti-
vator [36]. Mutations in Rab27A lead to an autosomal-
recessive immunodeficiency called Griscelli syndrome
type 2. Clinically, this syndrome is characterized by par-
tial albinism and hemophagocytic lymphohistocytosis.
Understanding the mechanisms of Rab27A mutations
may be helpful in early diagnosis and treatment [37]. An
elegant study recently demonstrated that Rab 27B con-
trols vesicle exocytosis and releases important growth
regulators into the tumor microenvironment, leading to
regulation of invasive growth and metastasis in
ER-positive human breast tumors [38]. This study also
suggested that increased expression of Rab27 is asso-
ciated with poor prognosis in humans [38] suggesting
Rab 27b may function like an oncogene.
Microarray analysis data indicate that Rab35 is highly
expressed in ovarian cancer. It also has been shown that
androgens may affect the expression of oncogenic
GTPases in ovarian cancer [29]. Rab35 is involved in T-
cell receptor and oocyte yolk protein recycling and cyto-
kinesis. Chua et al. (2010) have shown that Rab35 causes
actin to reconcile protrusion through either Rho GTPases
or effector fascin of actin bundling protein [39].
Rab4 and Rab14 are also involved in vesicle trafficking
and associate with the C-terminal domain of P-glycopro-
tein (P-gp), which induces signaling for a multi-drug-resis-
tance (MDR) mechanism in tumors. Overexpression of
Rab4, but not Rab14, decreases P-gp on the cell surface of
K562ADR cells, reducing the MDR phenotype by elevating
the intracellular addition of daunomycin [40]. Accordingly,
modulation of the spatial and temporal distribution of
P-gp may be a good therapeutic strategy for suppressing
the MDR phenotype.
Trafficking-independent tumorigenic regulators
Rab 23 binds to PSF (Polypyrimidine tract-binding pro-
tein (PTB)- associated splicing factor), a tumor suppres-
sor; PSF and VL30-1 RNA, a mouse retroelement
noncoding RNA, are involved in reversible regulation of
proto-oncogene transcription, cell proliferation, and
tumorigenesis in a mouse model. PSF represses tran-
scription by binding with the proto-oncogene Rab23;
the VL30-1 RNA binds with PSF to release it from
Rab23 for activating transcription. PSF and its binding
RNAs have a major function in reversible regulation of
mammalian cell proliferation and tumorigenensis.
Indeed, alteration in the expression of PSF and its bind-
ing RNAs may have potential as a therapeutic strategy
against cancer [41]. Human RAB37 (hRAB37) acts as a
metastasis-related tumor suppressor gene (TSG) in lung
cancer. Methylation in the promoter is the main
mechanism for down-regulation of hRAB37 [42]. Thus
Rab23 and Rab 37 regulate tumorigenesis through the
mechanisms other than trafficking.
Rab GTPases and Integrins Integrins are members of a
glycoprotein family that form heterodimeric receptors
involved in interaction between the cell and the sur-
rounding extracellular matrix (ECM). Nineteen alpha
subunits and eight beta subunits are paired to form 25
different integrins. Integrins control several biological
processes, including cell adhesion, cell migration, and
the progression of cancer and some other diseases
[43,44]. Integrins are also involved in transducing signals
from outside the cells to inside and from inside to out-
side the cells. The ligand binding abilities of integrins
are determined by the a/b subunit heterodimerization.
The ligands for integrins are several extracellular matrix
proteins including collagen, laminin, vitronectin and
fibronectin. Some integrins such as a5b1 interact with a
single ECM protein, fibronectin, however, usually integ-
rins recognize several distinct matrix proteins [45].
The cytoplasmic domains of integrins provide a key
connection between the ECM and intracellular proteins
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and signaling mechanisms [43]. Although both alpha
and beta subunits make important contributions to var-
ious aspects of integrin functions including signal trans-
duction, cell motility, cell adhesion and integrin
activation, the beta cytoplasmic domains are critical for
recruitment of integrins to focal contacts (the specia-
lized structures at cell-matrix junctions). Integrins can
also respond to signals generated inside the cells that
may impact on the cytoplasmic domain, which is often
referred to as inside-out signaling. For example, trunca-
tion of some integrin cytoplasmic domains prevents
integrin activation [46].
Integrins and Cell Adhesion
It is apparently clear that integrins can directly activate
intracellular signaling processes without the requirement
of growth factors. Integrin mediated adhesion activates
tyrosine phosphorylation of focal adhesion kinase (FAK)
[47,48], and FAK in turn binds to other signaling and
structural proteins including c-Src, PI3K, paxillin and
p130CAS. Furthermore, adhesion triggered activation of
ERK has been shown. In this scenario, upon cell adhe-
sion, FAK is recruited to focal contacts, phosphorylated
at Y397 and Src is recruited, which then phosphorylates
at other sites. FAK then binds to Grb2 and Grb2/SOS
complex activates Ras-Raf-MEK-ERK cascade [49]. In
addition, cell adhesion (integrin engagement) activates
Rho GTPases, which play an important role in cytoske-
letal regulation and cell migration [44].
Integrins and Cell Migration
Cell migration involves very well orchestrated events that
allow cells to attach to substratum and detach from it, to
protrude projections and directionally advance. Cell
motility consists of four major events including extension
of the lamellipod, formation of new focal adhesion at the
leading edge, breaking of adhesions at the rear end and
translocation of the cell mass [43]. Almost all of the
events of cell migration involve adhesion receptors espe-
cially integrins. As described above FAK associates with
focal adhesions and gets phosphorylated upon integrin
mediated cell attachment to the ECM. In several cell
types, FAK has been shown to promote cell migration
[50]. FAK directly binds to the adaptor protein that inter-
acts with activated p130 CAS. This complex promotes
cell migration and invasion of cancer cells through Rac
signaling cascade. Also ERK promotes cell migration by
regulation of actin-myosin assembly and cell contraction.
Thus, both ERK activation and CAS/CRK complexes
coordinately regulate cell migration (reviewed in [43].
Integrins and Endocytosis
The endocytosis and exocytosis cycle of integrins is a
key regulator of cell adhesion, migration, and the main-
tenance of cell polarity. Several recent reports indicate
that members of the Rab family regulate the internaliza-
tion of integrin and its recycling back to the cell
membrane. The original concept has been that exocyto-
sis at their leading edge helps cells move by producing
new adhesion receptors, which are internalized at the
rear end of the cells. The cytoplasmic domains of integ-
rins have a major function in the trafficking of integrins.
A membrane proximal YRRF motif in beta integrins and
a GFFKR motif in alpha integrin are important in regu-
lating membrane traffic [51,52].
The endocytosis of integrins occurs through clathrin-
dependent and -independent pathways. Recently, it has
become clear that integrins are internalized at focal
adhesions near the leading edge of cells [53]. Thus,
integrin trafficking seems to be important in maintain-
ing migrational polarity and localizing integrin signaling
at the front of cells. Several Rab GTPases control integ-
rin recycling. Rab 4 effector protein, Rab 5, Rab 21, Rab
11, Rab 25, Rab 4A, Rab 8A, and Rab 11FIP1 are of
great interest in this context.
Rab 4 effector protein (Rab IP4) is involved in recy-
cling avb3 integrins. Inhibition of Rab IP4 function
blocks integrin recycling, leading to inhibition of cell
adhesion and cell spreading [54]. The integrin transloca-
tion from the trailing edge toward the advancing lamel-
lipodium seems to be important for the speed and
direction of cell migration. In migrating cells, integrin
distribution is polarized in the leading edge; endosomal
transport is a major factor in this translocation. Consis-
tent with this hypothesis, suppression of Rab IP4 does
not allow avb3 integrin to localize in the leading edge
of migrating cells. Several reports indicate that integrin-
containing vesicles move from the rear end of cells to
the lamellipodia and that dysregulation of integrin func-
tion leads to the pathogenesis of cancer. Integrin
engagement promotes proliferation and the apoptotic
resistance of cancer cells, and regulates cell migration
and invasion during metastasis.
Rab5 and Rab 21 regulate endocytosis and the recycling
of beta integrins. Rab5 family GTPases regulates endocy-
tosis through the movement of endocytic vesicles along
microtubules. Caspase-8 has a major part in controlling
cellular responses to promote apoptosis, proliferation,
and cell migration. Protein caspase-8-mediated signaling
from integrins is regulated by Rab5. Integrin-mediated
activation of Rab5 enhances colocalization and coprecipi-
tation of integrins with caspase-8. Rab5-mediated inter-
nalization and recycling of b1 integrins are increased by
caspase-8. Knockdown of Rab5 prevents integrin signal-
ing from activating Rac to promote cell migration and
the apoptotic signaling pathway. Caspase-8-driven cell
migration critically requires Rab 5. Thus, Rab 5 is an
essential integrator of caspase-8-mediated signal trans-
duction to regulate cell survival and migration [55].
Rab 21 enhances cell adhesion and migration by indu-
cing integrin trafficking. Rab21 is present in early
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endosomes; it functions in the endocytosis of integrins,
cell-extracellular matrix adhesion, and motility [52]. In
its active form, Rab 21 associates more strongly with
beta1 integrin in endocytic vesicles and thus, nucleotide
exchange is important in endocytosis. Transport by
microtubule- or actin-based motor proteins facilitates
timely orientation of vesicles for fusion in vivo. Rab-
GTPases are perfect factors to regulate the movement of
vesicles by controlling the motor protein recruitment of
specific target membranes [56].
Carcinoma-associated fibroblasts (CAFs) can promote
the progression of tumors in different ways, generating a
situation that enables the invasion of cancer cells through
extracellular remodeling. Rab21 is involved in promoting
cancer cell invasion promoted by CAFs. Rab21 is required
for CAFs to promote invasion by cancer cells and facili-
tates integrin a5 accumulation for force-mediated matrix
remodeling at the plasma membrane [57].
Tumor cell invasion and metastasis is increased by
hypoxia, which modifies Rab11, a vital molecule for vesi-
cular trafficking through maintenance of microtubule
stability. Hypoxia increases integrin a6b4 expression;
this increase depends on Rab11 [58]. The oncogene
R-Ras, which enhances integrin-mediated cell adhesion
and spreading, localizes at the leading edge of migrating
cells to regulate membrane protrusion. R-Ras undergoes
endocytosis by various pathways, one of which is
mediated by vesicles of Rab11. Constitutively, active
R-Ras increases the number of Rab11 vesicles. R-Ras is
also colocalized with b1-integrin [59]. Thus, integrins
appear to have a major part in regulation that occurs
between R-Ras and Rab11.
a5b1 integrin cycles between an intracellular Rab 25
compartment and the pseudopodial tip region of migrat-
ing cells, where Rab 25 is also localized. Chia and Tang
have reported that Rab25 is important in epithelial
tumor progression and aggressiveness, associating with
a5b1 integrin to increase tumor cell invasion. Rab25
associates with a5b1 integrin to enhance migration and
invasion of cells in three-dimensional microenviron-
ments, and directs its recycling to dynamic ruffling pro-
trusions at the leading edge of migrating cells [60].
Rab25 acts directly or through its effector, Rab-coupling
protein, to hold together integrin and epidermal growth
factor receptor. Rab25, which induces both oncogenic
recycling and signaling of the integrin and epidermal
growth-factor receptor [25,53] also controls a5b1 integ-
rin at the leading edge, thereby promoting an invasive
mode of migration in three-dimensional matrices. Such
invasion is mainly dependent on fibronectin, a5b1 integ-
rin, and the interaction of Rab25 with b1 integrin [61].
The association of Rab25 and a5b1 integrin causes
enhanced localization of vesicles that deliver integrin to
the plasma membrane [53]. In human colorectal
adenocarcinomas, Rab25 functions as a tumor suppres-
sor at independent cancer stages by regulating protein
trafficking to cell surfaces [25].
The VEGF receptor, VEGFR, is one of the most impor-
tant positive regulators of new blood vessel growth. Its
downstream signaling events have been well studied. Acti-
vation of VEGFR1 enhances a Rab4A-dependent pathway
that transports avb3-integrin from early endosomes to the
plasma membrane. This signaling pathway is associated
with VEGF-driven fibronectin polymerization in endothe-
lial cells. Rab4a and the integrin avb3 are involved in
VEGFR1-mediated promotion of endothelial tubule
branching in an organotypic model of angiogenesis [62].
The RAB-coupling protein (RAB11FIP1) is a driving
force for the 8p11-12 amplicon in human breast cancer
and mouse xenograft models of mammary carcinogen-
esis. One study showed that a5b1 associates with
RAB11FIP1 at the tips of pseudopods, causing increased
recycling of a5b1 integrin[63]. Since Rab 25 binds to
Rab11 FIP1/RCP, it is hypothesized that interaction
between them may control a5b1 trafficking. In summary
all these reports suggest that Rab GTPases play an
important role in integrin trafficking that regulates
membrane protrusion activity, which in turn aid in can-
cer cell migration and invasion.
Conclusion
The involvement of Rab GTPases in regulating mem-
brane trafficking between organelles occurs by recruit-
ment of effector proteins. Immunodeficiencies, cancer,
and neurological disorders are associated with functional
impairments of Rab signaling pathways [12]. Alteration
or mutation of Rab proteins and/or their effectors may
cause many human diseases, including cancer.
Alterations in Rab25, Rab7, Rab5, and Rab11 have
been reported to cause different types of cancers. Neu-
ronal dysfunction is caused by abnormalities in Rab1
and Rab7; retinal degeneration is caused by abnormal-
ities in Rab8; and both immune and pigmentation disor-
ders are caused by abnormalities in Rab27 and Rab38
[18,64-66]. Hence, Rab GTPases could serve as primary
drug targets. Their interactive molecules may provide
pathways for novel therapeutic interventions.
Additional material
Additional file 1: A. File showing various types of Rab GTPases and
their localization. Detailed references are given in the additional file B.
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